RBC Capital Reiterates Outperform on Abbott Laboratories, Maintains $128 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh has reiterated an Outperform rating on Abbott Laboratories (NYSE:ABT) and maintained a price target of $128.
January 25, 2024 | 3:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Shagun Singh reaffirms an Outperform rating on Abbott Laboratories with a $128 price target.
The reiteration of an Outperform rating by a major analyst like RBC Capital tends to instill confidence in investors and can positively influence the stock price in the short term. The maintained price target of $128 suggests a potential upside from the current trading level, assuming the stock is trading below this target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100